1. Inicio
  2. Publicaciones
  3. PCSK9 Inhibitors in Heart Transplant Recipients

PCSK9 Inhibitors in Heart Transplant Recipients

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Valero M.J.
  • Ortiz-Bautista C.
  • Gonzalez-Martín J.
  • Simón-Ramon C.
  • Barragán-Amado A.F.
  • Carrasco F.
  • Groba-Marco M.D.V.
  • García-Romero E.
  • Castrodeza J.
  • Blázquez Z.
  • Sousa I.
  • Bermejo J.
  • Martínez-Sellés M.

Grupos

Abstract

Background: Dyslipidemia is highly prevalent after heart transplantation (HT). We evaluated the efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in a national cohort of HT recipients. Methods: In this retrospective multicenter study, we included HT recipients from 8 centers in Spain. The primary analysis assessed changes in total and LDL cholesterol at 1 month. Secondary outcomes included the development of donor-specific HLA antibodies (DSA), coronary allograft vasculopathy (CAV), and rejection. Results: Thirty-six HT recipients received PCSK9 inhibitors between May 2018 and September 2024. Median total cholesterol decreased from 195 mg/dL (170.5 to 233.5) to 124 mg/dL (96 to 156) at 1 month (reduction of 83 mg/dL [45 to 96]). Median LDL cholesterol decreased from 119.5 mg/dL (95 to 155) to 50 mg/dL (30 to 75; reduction of 71 mg/dL [43 to 97]). The prevalence of DSA, CAV, and rejection did not differ significantly before and after treatment (DSA: 20% vs 38.1%, P = .25; CAV: 30.56% vs 38.89%, P = .25; rejection: 19.4% vs 8.3%, P = .68). Conclusions: In HT recipients, PCSK9 inhibitors were associated with a marked reduction in LDL cholesterol, with no apparent safety signal. These findings support their use in patients with suboptimal lipid control, although their impact on clinical outcomes warrants further investigation. © 2026 The Authors

Datos de la publicación

ISSN/ISSNe:
0041-1345, 1873-2623

TRANSPLANTATION PROCEEDINGS  ELSEVIER SCIENCE INC

Tipo:
Article
Páginas:
1152-1155
PubMed:
42321111
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
0,286 SCImago ℠
Cuartil:
Q3 SCImago ℠

Citas Recibidas en Web of Science: 1

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Cholesterol, LDL; Dyslipidemias; Female; Graft Rejection; Heart Transplantation; Humans; Male; Middle Aged; PCSK9 Inhibitors; Proprotein Convertase 9; Retrospective Studies; Spain; low density lipoprotein cholesterol; PCSK9 inhibitor; PCSK9 protein, human; proprotein convertase 9; adverse event; blood; clinical trial; drug therapy; dyslipidemia; epidemiology; female; graft rejection; heart transplantation; human; male; middle aged; multicenter study; prevention and control; retrospective study; Spain

Cita

Compartir